Cox, S
Powell, C
Carter, B
Hurt, C
Mukherjee, Somnath
Crosby, Thomas David Lewis
Article History
Received: 16 March 2016
Accepted: 18 April 2016
First Online: 21 June 2016
Competing interests
: Merck Serono supplied free cetuximab, drug labelling and distribution in the SCOPE1 trial but had no role in the design of the study, collection, analysis and interpretation of the data or writing of this report. SC has received educational sponsorship from Merck Serono and Pfizer to attend an international conference. The remaining authors declare no conflict of interest.